HIV Infections
Conditions
Keywords
Vaccines, Synthetic, Drug Evaluation, Acquired Immunodeficiency Syndrome, AIDS Vaccines
Brief summary
To test the safety and immunogenicity of rgp 120/HIV-1IIIB vaccine in HIV-1 seropositive adult patients.
Interventions
BIOLOGICALrgp120/HIV-1IIIB
Sponsors
Genentech, Inc.
Study design
Primary purpose
PREVENTION
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients must have the following: * Stage 1 or 2 Walter Reed clinical staging of HIV infected individuals. * The ability to understand and sign a written informed consent form, which must be obtained prior to study entry. * Be available for 24 weeks so that follow up may be completed. * Qualify for care as Department of Defense health care beneficiary.
Exclusion criteria
Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Prior history of clinically significant cardiac, pulmonary, hepatic, renal, neurologic or autoimmune disease, other than HIV-1 infection, and in less than average general health as determined by a medical history, physical examination, and the required laboratory test results. Concurrent Medication: Excluded: * Corticosteroids or other known immunosuppressive drugs. * Any experimental agents. Patients with the following are excluded: * Prior history of clinically significant cardiac, pulmonary, hepatic, renal, neurologic or autoimmune disease, other than HIV-1 infection, and in less than average general health as determined by a medical history, physical examination, and the required laboratory test results. Prior Medication: Excluded within 30 days of study entry: * Zidovudine or other anti-retroviral agents.
Countries
United States
Outcome results
None listed